Tipifarnib, a farnesyltransferase inhibitor that inhibits HRAS processing, has shown some activity in HRAS-mutant HNSCC demonstrating a response rate of 55% in Phase 2 trials enrolling refractory/metastatic HNSCC patients after progressing on standard treatment options [48]. The gene discussed is HRAS; the disease is head and neck squamous cell carcinoma.